These studies demonstrated the therapeutic effect of pembrolizumab in patients with PD-L1-positive cervical cancer and formed the basis for pembrolizumab to be approved by the FDA as a treatment for patients with progressive or recurrent cervical cancer with PD-L1 positivity. The gene discussed is CD274; the disease is cervical cancer.